These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23474764)

  • 21. Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer.
    Kawano T; Inokuchi J; Eto M; Murata M; Kang JH
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.
    Havugimana PC; Goel RK; Phanse S; Youssef A; Padhorny D; Kotelnikov S; Kozakov D; Emili A
    Nat Commun; 2022 Jul; 13(1):4043. PubMed ID: 35831314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
    Saleiro D; Wen JQ; Kosciuczuk EM; Eckerdt F; Beauchamp EM; Oku CV; Blyth GT; Fischietti M; Ilut L; Colamonici M; Palivos W; Atsaves PA; Tan D; Kocherginsky M; Weinberg RS; Fish EN; Crispino JD; Hoffman R; Platanias LC
    Nat Commun; 2022 Apr; 13(1):1750. PubMed ID: 35365653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells.
    Cieslikowski WA; Haber T; Krajnak S; Anic K; Hasenburg A; Mager R; Thüroff JW; Brenner W
    EXCLI J; 2021; 20():1585-1596. PubMed ID: 34924906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic Assessment of Rottlerin from
    Manhas D; Gour A; Bhardwaj N; Sharma DK; Sharma K; Vij B; Jain SK; Singh G; Nandi U
    ACS Omega; 2021 Dec; 6(48):32637-32646. PubMed ID: 34901612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. L-plastin Ser5 phosphorylation is modulated by the PI3K/SGK pathway and promotes breast cancer cell invasiveness.
    Machado RAC; Stojevski D; De Landtsheer S; Lucarelli P; Baron A; Sauter T; Schaffner-Reckinger E
    Cell Commun Signal; 2021 Feb; 19(1):22. PubMed ID: 33618712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equivocal, explicit and emergent actions of PKC isoforms in cancer.
    Parker PJ; Brown SJ; Calleja V; Chakravarty P; Cobbaut M; Linch M; Marshall JJT; Martini S; McDonald NQ; Soliman T; Watson L
    Nat Rev Cancer; 2021 Jan; 21(1):51-63. PubMed ID: 33177705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional proteomic analysis reveals roles for PKCδ in regulation of cell survival and cell death: Implications for cancer pathogenesis and therapy.
    Speidel JT; Affandi T; Jones DNM; Ferrara SE; Reyland ME
    Adv Biol Regul; 2020 Dec; 78():100757. PubMed ID: 33045516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes.
    Leung KK; Wilson GM; Kirkemo LL; Riley NM; Coon JJ; Wells JA
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7764-7775. PubMed ID: 32205440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers.
    Nelson LJ; Wright HJ; Dinh NB; Nguyen KD; Razorenova OV; Heinemann FS
    Am J Pathol; 2020 Feb; 190(2):484-502. PubMed ID: 31843498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGF receptor and PKCδ kinase activate DNA damage-induced pro-survival and pro-apoptotic signaling via biphasic activation of ERK and MSK1 kinases.
    Ohm AM; Affandi T; Reyland ME
    J Biol Chem; 2019 Mar; 294(12):4488-4497. PubMed ID: 30679314
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.
    Schwill M; Tamaskovic R; Gajadhar AS; Kast F; White FM; Plückthun A
    Sci Signal; 2019 Jan; 12(565):. PubMed ID: 30670633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.
    Lee PC; Fang YF; Yamaguchi H; Wang WJ; Chen TC; Hong X; Ke B; Xia W; Wei Y; Zha Z; Wang Y; Kuo HP; Wang CW; Tu CY; Chen CH; Huang WC; Chiang SF; Nie L; Hou J; Chen CT; Huo L; Yang WH; Deng R; Nakai K; Hsu YH; Chang SS; Chiu TJ; Tang J; Zhang R; Wang L; Fang B; Chen T; Wong KK; Hsu JL; Hung MC
    Cancer Cell; 2018 Dec; 34(6):954-969.e4. PubMed ID: 30537515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved synergistic anticancer efficacy of quercetin in combination with PI-103, rottlerin, and G0 6983 against MCF-7 and RAW 264.7 cells.
    Maurya AK; Vinayak M
    In Vitro Cell Dev Biol Anim; 2019 Jan; 55(1):36-44. PubMed ID: 30413935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of sigma-1 receptor in MCF-7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway.
    Wu Y; Bai X; Li X; Zhu C; Wu ZP
    Oncol Lett; 2018 Nov; 16(5):6763-6769. PubMed ID: 30405820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein kinase C: perfectly balanced.
    Newton AC
    Crit Rev Biochem Mol Biol; 2018 Apr; 53(2):208-230. PubMed ID: 29513138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a small-molecule protein kinase Cδ-selective activator with promising application in colon cancer therapy.
    Bessa C; Soares J; Raimundo L; Loureiro JB; Gomes C; Reis F; Soares ML; Santos D; Dureja C; Chaudhuri SR; Lopez-Haber C; Kazanietz MG; Gonçalves J; Simões MF; Rijo P; Saraiva L
    Cell Death Dis; 2018 Jan; 9(2):23. PubMed ID: 29348560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase C as a tumor suppressor.
    Newton AC
    Semin Cancer Biol; 2018 Feb; 48():18-26. PubMed ID: 28476658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-dependency of PKCδ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
    Ohm AM; Tan AC; Heasley LE; Reyland ME
    Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor.
    Newton AC; Brognard J
    Trends Pharmacol Sci; 2017 May; 38(5):438-447. PubMed ID: 28283201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.